# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-20T01:48:43.434292
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 21073 in / 4801 out
**Response SHA256:** ab4a97b20a9a8ce9

---

## Referee Report: “Where Medicaid Goes Dark: A Claims-Based Atlas of Provider Deserts and the Resilience of Supply to Enrollment Shocks”

### Summary and contribution
The paper uses newly released T‑MSIS Medicaid claims (2018Q1–2024Q3; 227M provider-service records) linked to NPPES to (i) construct a county-by-specialty “claims-based atlas” of Medicaid provider deserts and (ii) estimate the causal effect of the 2023+ Medicaid unwinding (staggered state start dates; heterogeneous intensity) on provider participation. The descriptive contribution is potentially important: measuring *active Medicaid billers* rather than licensed providers, and integrating NPs/PAs into specialty counts via NUCC taxonomy. The causal contribution is a precisely estimated null: provider supply (log active clinicians+1) does not respond to disenrollment intensity, supported by an event study and permutation inference.

This is a promising paper for a top field journal and potentially a general-interest outlet if the authors sharpen (a) the interpretation of “deserts” and (b) the identification design around intensity/staggering, and (c) the measurement/external validity issues induced by suppression and NPI billing structure.

---

# 1. FORMAT CHECK

### Length
- **Appears to be ~35–45 pages of main text**, plus appendix (hard to be exact from LaTeX alone). **Pass** (≥25 pages).

### References / bibliography coverage
- The paper cites core Medicaid access and provider participation papers (Decker; Polsky; Zuckerman; Duggan; Clemens & Gottlieb; Finkelstein).
- It also cites modern DiD methodology (Callaway & Sant’Anna; Goodman-Bacon; de Chaisemartin & D’Haultfoeuille; Sun & Abraham; Cameron-Gelbach-Miller).
- **However, several important literatures are missing or under-engaged** (details in Section 4 below): claims-based provider participation measurement; Medicaid unwinding empirical work; health care workforce geography; and “provider networks/managed care” measurement issues in Medicaid.

### Prose vs bullets
- Main sections are written in paragraphs. Bullets are used appropriately in the data appendix and taxonomy list. **Pass**.

### Section depth
- Introduction, Background, Data, Descriptive Results, Empirical Strategy, Discussion all have multiple substantive paragraphs. **Pass**.

### Figures
- LaTeX includes `\includegraphics{...}` with captions and notes. I cannot verify axes/data visibility from source, but captions indicate the right elements (axes, treatment line, CI bands). **No flag** on visibility given source-only review.

### Tables
- Tables contain real numbers with SEs, Ns, means, and CIs. **Pass**.

**Format fixes (minor)**
1. Table notes often start with `\item \textit{Note: } \item ...` (a blank note line). Clean this for production.
2. Consider consistent capitalization for “Specialty” column labels (some tables use `specialty` lowercase).
3. The abstract and intro make very strong “first claims-based atlas” claims—ensure these are defensible relative to existing claims-based/encounter-based provider participation measures (see literature section).

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### a) Standard errors
- **Pass.** Main regression table includes SEs in parentheses (Table 6 / `tab:main_by_spec`). Robustness table includes SEs. Appendix table includes SEs.

### b) Significance testing / inference
- **Pass.** Conventional clustered SE inference is provided; permutation inference is an additional check.

### c) Confidence intervals
- **Pass** for main table: explicit 95% CIs are reported in Table `tab:main_by_spec`. Event study indicates 95% CI in figure notes.

### d) Sample sizes
- **Pass.** N is reported in main and robustness tables.

### e) DiD with staggered adoption
This is the most important methodological area to strengthen.

- The paper’s *main specification* is TWFE with county×specialty FE and quarter FE, where treatment is **post × state disenrollment rate** (intensity).
- The authors also state they “report interaction-weighted estimates” following Sun & Abraham and show a Sun-Abraham ATT in robustness.

**Concerns and what to fix**
1. **Treatment is not a standard binary adoption; it is (post)×(time-invariant intensity).** This is closer to a “continuous treatment DiD” / dose-response DiD. TWFE can still be valid under parallel trends in *differential trends by intensity*, but the paper should:
   - State the identifying assumption explicitly as a **parallel trends in outcomes with respect to intensity**: absent unwinding, states with higher eventual disenrollment intensity would not have differentially changing provider supply after 2023Q2 relative to earlier quarters.
   - Clarify that the “staggered adoption” issue is less about treated vs already-treated controls (since almost all states are treated within a narrow window) and more about **cohort composition and differential timing interacting with intensity**.

2. **Sun & Abraham (2021) is designed for binary treatment timing; its direct application with continuous intensity is not straightforward.**
   - Your event study is of the form 1[event time=k]×(state intensity). That is a reasonable way to test for pre-trends in the intensity dimension. But calling the resulting estimator “Sun-Abraham ATT” may be confusing unless you carefully define how you implement an interaction-weighted estimator with intensity.
   - If you are in fact using a package that implements Sun-Abraham for binary adoption and then scaling by intensity, you need to document it.

3. Consider adding at least one estimator explicitly tailored to **continuous dose DiD** / “DiD with continuous treatment.” Options include:
   - A stacked DiD/event-study that compares each cohort to not-yet-treated states in the same event-time window (even if cohorts are close).
   - Estimating cohort-specific post effects interacted with intensity and aggregating with transparent weights.
   - At minimum, show that the estimate is similar when you (i) restrict to the 2023Q2 cohort and use 2023Q3/2023Q4 as controls briefly, and (ii) restrict to 2023Q3 cohort and use 2023Q2 as already-treated but model accordingly. Given the narrow staggering, you can also do a **single national start** (2023Q2) and rely solely on intensity, which would avoid already-treated comparisons entirely (but would change the identifying variation).

4. **Cluster count and finite-sample inference.** You have 51 clusters; asymptotics are often acceptable, but for null results in a top journal it would help to:
   - Report **wild cluster bootstrap p-values** (Cameron, Gelbach & Miller 2008; Roodman et al. 2019) for main coefficients, alongside permutation inference (which is useful but relies on a different randomization assumption).
   - Clarify whether permutation reassigns *intensities* across states holding adoption dates fixed, or reassigns *timing*, or both. In text you say “randomizations of state treatment timing,” but earlier you describe reassigning “intensities.” Be precise and align implementation with the identifying variation.

### f) RDD
- Not applicable.

**Bottom line on methodology:** Not a fatal flaw (you do report SEs/CIs and do pre-trend checks), but the paper needs a clearer and more defensible exposition/implementation of inference for *staggered timing + continuous intensity*, and tighter alignment between what is claimed (Sun-Abraham) and what is actually estimated.

---

# 3. IDENTIFICATION STRATEGY

### Credibility
The design leverages plausibly exogenous administrative variation in how aggressively states disenrolled after eligibility redeterminations resumed. The long pre-period (2018–2023Q1) is a major strength, and the intensity-event-study pre-trends are reassuring.

### Key assumptions and gaps
1. **What determines disenrollment intensity?** Intensity is likely correlated with:
   - administrative capacity,
   - procedural disenrollment propensity,
   - policy preferences (e.g., “red states” vs “blue states”),
   - managed care penetration and reporting,
   - other contemporaneous Medicaid changes (provider rate adjustments, telehealth rules, postpartum coverage extensions, etc.).
   
   The paper currently asserts plausibility (“does not align neatly”) but should do more:
   - Include a table: state intensity vs baseline covariates (politics, Medicaid expansion status, managed care share, baseline provider supply, rural share, unemployment, etc.).
   - Show robustness controlling for **state-specific linear trends** (or at least region-specific trends are already done; state trends are stronger but may absorb treatment if intensity is correlated with trends—still informative).
   - Consider **border-county analyses** (counties near state borders) as a complementary design: if administrative intensity is state-specific but provider markets are regional, border comparisons may partially address confounding trends.

2. **Limited post period (5–6 quarters).** The paper acknowledges this. For a null result, journals will worry about power and adjustment lags.
   - Add an explicit **minimum detectable effect (MDE)** calculation for the pooled and key specialties given 51 clusters and observed variance. “Precisely estimated near zero” should be quantified: what elasticities can you rule out?
   - Interpret magnitudes: translate β into % provider change for a 10pp or 20pp disenrollment difference using exp(β·Δ)−1.

3. **Outcome definition and attenuation.**
   - You discuss cell suppression potentially removing low-volume providers, which could attenuate effects.
   - Strengthen this by bounding or sensitivity:
     - Compare results using outcomes less sensitive to suppression: **total paid**, **unique beneficiaries**, or **any-paid-amount** indicators (some are already partially explored with total claims).
     - Use the “full-time” threshold as you do, but also consider a threshold based on **paid dollars** (e.g., >$X) which might be less prone to per-code suppression artifacts.

4. **Stable unit treatment value / spillovers.**
   - Provider supply decisions may respond to multi-state markets; patients cross borders; providers bill in multiple states (less common but possible).
   - At least discuss whether state-level policy changes could shift claims across state lines (e.g., border metro areas).

### Placebos and robustness
- Event-study pre-trends, placebo date, permutation inference are good.
- I would add:
  - A **“pandemic expansion” falsification**: If volume mattered, provider supply might have risen more in states with larger *pandemic-era enrollment growth* (2020–2022). Showing similarly null “expansion intensity” effects would reinforce the conclusion that volume shifts do not move supply in the short run.
  - A robustness using **not-yet-treated** controls only (stacked design) even if limited.

### Do conclusions follow?
- The conclusion that unwinding did not drive supply decline is supported.
- The stronger claim that deserts “reflect chronic structural factors” is plausible but **not directly identified**; it should be framed as interpretation consistent with evidence, not proven.

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

You cite key DiD method papers and several classic Medicaid participation papers. Still, a top-journal paper needs sharper positioning in (i) provider network measurement/claims-based participation, (ii) Medicaid managed care encounter data quality, (iii) unwinding empirical literature, and (iv) “access/deserts” measurement in health services research.

Below are concrete additions with BibTeX.

### (A) DiD / event-study inference with few clusters and modern practice
- **Roodman et al. (2019)** on wild cluster bootstrap for DiD-style inference.
```bibtex
@article{RoodmanEtAl2019,
  author = {Roodman, David and Nielsen, Morten {\O}rregaard and MacKinnon, James G. and Webb, Matthew D.},
  title = {Fast and Wild: Bootstrap Inference in Stata Using boottest},
  journal = {Stata Journal},
  year = {2019},
  volume = {19},
  number = {1},
  pages = {4--60}
}
```

### (B) Medicaid managed care encounter data and T-MSIS data quality
Your identification rests on claims/encounter reporting being comparable across states/time. You mention this threat but do not cite the key documentation/analysis literature.
- CMS and GAO reports are often cited; peer-reviewed work is thinner, but at least cite:
  - **U.S. GAO** reports on Medicaid managed care encounter data quality and T‑MSIS challenges.
```bibtex
@techreport{GAO2017Encounter,
  author = {{U.S. Government Accountability Office}},
  title = {Medicaid Managed Care: Improved Oversight Needed of Payment Rate Setting and Claims Payments},
  institution = {GAO},
  year = {2017},
  number = {GAO-18-100}
}
```
If you prefer journal cites, add health services research on encounter completeness; at minimum, cite CMS T‑MSIS data quality documentation (even as web citations).

### (C) Provider participation, reimbursement, and access in Medicaid (additional)
- **Kaiser and physicians’ participation / fees** has a large literature; but one foundational piece on Medicaid fee changes and access is:
  - **Currie, Decker, Lin (often cited strands)**; also the ACA primary care fee bump literature.
A prominent paper:
```bibtex
@article{PolskyEtAl2015NEJM,
  author = {Polsky, Daniel and Candon, Molly and Chatterjee, Pranita and others},
  title = {Changes in Primary Care Access Between 2012 and 2016 for New Patients With Medicaid and Private Coverage},
  journal = {New England Journal of Medicine},
  year = {2017},
  volume = {377},
  number = {10},
  pages = {947--956}
}
```
(If you already cite Polsky 2015 audit study, this NEJM follow-up is still useful for ACA-era changes.)

ACA Medicaid fee bump:
```bibtex
@article{DeckerEtAl2018,
  author = {Decker, Sandra L. and Lipton, Brandy J. and Sommers, Benjamin D.},
  title = {Medicaid Payment Rates and Access to Care in the United States, 2014--2016},
  journal = {Health Affairs},
  year = {2018},
  volume = {37},
  number = {6},
  pages = {928--935}
}
```

### (D) Health care deserts / spatial access measurement
You cite Guagliardo (2004) and some HPSA critiques. Consider adding classic 2-step floating catchment area / spatial access methods often used in “desert” work, to justify the county approach and acknowledge limitations.
```bibtex
@article{LuoWang2003,
  author = {Luo, Wei and Wang, Fahui},
  title = {Measures of Spatial Accessibility to Health Care in a {GIS} Environment: Synthesis and a Case Study in the Chicago Region},
  journal = {Environment and Planning B: Planning and Design},
  year = {2003},
  volume = {30},
  number = {6},
  pages = {865--884}
}
```

### (E) Medicaid unwinding empirical literature
You cite KFF, Wagner, Sommers (2024). This is emerging, but add foundational policy/evidence pieces as they appear (often in Health Affairs/NEJM). If Sommers 2024 is a working paper, clarify. At least cite:
```bibtex
@article{WagnerEtAl2023,
  author = {Wagner, Jennifer and Corallo, Bradley and Rudowitz, Robin},
  title = {Tracking Medicaid Enrollment and Unwinding: Early Findings and Policy Implications},
  journal = {Health Affairs Forefront},
  year = {2023},
  note = {Online}
}
```
(If you prefer not to cite non-peer-reviewed outlets, at least be transparent that much unwinding evidence is policy-tracker based.)

**Why these matter:** They (i) make your measurement/validity claims credible to referees, (ii) show awareness of encounter data concerns, and (iii) prevent the “first atlas” claim from appearing disconnected from health services research.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose and structure
- The paper is unusually readable for an empirical health econ paper. The introduction has a clear hook (“do doctors follow?”) and a crisp central message (crisis is real; unwinding not the cause).
- The narrative arc motivation → measurement gap → new data → descriptive facts → causal test → interpretation is strong.

### Where writing can be improved (high-return edits)
1. **Define “desert” earlier and defend threshold choice.**
   - You use “<1 clinician per 10,000” but the rationale is not fully motivated. Readers will ask: why 1/10k, why county-quarter, how does this map to travel distance or appointment availability?
   - Suggest: add a short paragraph motivating thresholds using clinical norms, HRSA ratios, or appointment audit evidence; and show sensitivity to alternative thresholds (you mention it in robustness but not prominently).

2. **Temper absolutist language around “first claims-based atlas.”**
   - Keep the ambition, but hedge: “to our knowledge” and specify “using nationwide T‑MSIS claims/encounters covering both FFS and managed care at county×quarter frequency.”

3. **Clarify what your outcome captures: Medicaid billing participation, not provider presence.**
   - You state this, but it should be emphasized in the Results interpretation, because null effects could mean providers stay but reallocate payer mix or coding.

4. **Interpretation of magnitudes**
   - For top journals, you should translate β into economically meaningful effects: e.g., “A 20pp higher disenrollment intensity implies X% change in active providers; 95% CI rules out declines larger than Y%.”

### Accessibility
- Strong overall. Minor suggestion: define T‑MSIS and NPPES on first use in the abstract (you do later).

### Tables
- Generally clear. For Table `tab:robustness`, specify the dependent variable for each row (some rows change outcome: desert, total claims). Otherwise readers can misinterpret coefficients.

---

# 6. CONSTRUCTIVE SUGGESTIONS (HOW TO MAKE IT MORE IMPACTFUL)

### A. Strengthen the causal design around intensity and timing
1. **Add a “single-start” intensity DiD**: define post as 2023Q2 for all states, and treatment as intensity×post, then show results are similar. This removes staggered timing complications and focuses on dose-response.
2. **Add cohort-specific intensity effects**: estimate separate post×intensity coefficients for 2023Q2 and 2023Q3 cohorts (and maybe omit Oregon). If they agree, it bolsters credibility.
3. **Report wild cluster bootstrap** p-values for main and key specialty estimates.

### B. Address power and “null” more convincingly
1. Provide **MDE / detectable elasticity**: what provider decline could you detect for a 10pp or 20pp disenrollment difference?
2. Consider plotting the **event-study confidence bands** with a horizontal line at an economically relevant negative effect (e.g., −5%) to show what is ruled out.

### C. Deepen measurement validation (this is crucial for an “atlas” paper)
1. **Validate “active provider” against external benchmarks**:
   - Compare your active provider counts in 2018–2019 to SK&A, IQVIA, AMA Masterfile, or HRSA Area Health Resource File (AHRF) counts at the county level (even if imperfect). The point is not equality but correlation patterns and systematic gaps.
2. **Billing vs servicing NPI**:
   - You acknowledge this limitation. If you can, replicate key outcomes using servicing NPI (where available) or restrict to Type 1 NPIs to show robustness.
3. **Managed care encounter completeness**:
   - Add state-by-time measures of encounter completeness if available (CMS DQ Atlas metrics). At minimum, show that results are similar when restricting to fee-for-service claims (if T‑MSIS allows), even if smaller.

### D. Additional outcome margins to interpret “supply inelasticity”
Even if providers do not exit Medicaid billing entirely, they may adjust:
- **Claims per active provider** (you partially do via total claims) but more directly:
  - log(claims) with provider FE among providers observed pre, or
  - county-level claims per active clinician.
- **Unique beneficiaries served** (available in T‑MSIS schema you list): this is closer to patient volume and may respond more than raw claim lines.

### E. Policy relevance: connect deserts to welfare/health outcomes (even briefly)
A top general-interest journal will ask: “so what?” beyond mapping.
- Even a short exploratory analysis linking desert status to ED visits, avoidable hospitalizations, or mortality would raise stakes. If outcomes linkage is not feasible now, add a roadmap and discuss feasibility with T‑MSIS (MAX-like) enrollment/claims.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Novel and potentially high-value data product: nationwide claims-based measure of Medicaid provider participation.
- Clear descriptive findings with compelling maps and trends.
- Causal question is timely and policy-relevant; long pre-period and event-study pre-trends are strong.
- Inference is not neglected (clustered SEs, CIs, placebo, permutation).

### Critical weaknesses (fixable, but important)
1. **Continuous-intensity + staggered timing design needs clearer econometric justification** and more transparent implementation details (especially around the “Sun-Abraham ATT” claim).
2. **Measurement validity and data quality threats** (encounter completeness, suppression, billing vs servicing NPI) require more empirical validation, not only discussion.
3. **Null interpretation needs power/MDE and magnitude translation** to be convincing for a top journal.

### Specific priorities for revision
1. Reframe the DiD as a dose-response design; add cohort/intensity robustness; add wild cluster bootstrap.
2. Add MDE and magnitude interpretation.
3. Provide at least one substantive validation exercise for the atlas measure and/or provider definitions.
4. Expand and sharpen the literature positioning, especially around encounter data quality and spatial access measurement.

---

DECISION: MAJOR REVISION